Evidence map›Paper›PMID 35223501›Full record

ArticleFrontiers in oncology2022

Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.

Mahlatse C M Kgokolo, Katherine Anderson, Shalate C Siwele, Helen C Steel, Luyanda L I Kwofie, Mike M Sathekge, Pieter W A Meyer, Bernardo L Rapoport, Ronald Anderson

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. TIM-3 in AML: pathogenic roles and therapeutic targetability.Clinical and experimental medicine · 2026
    Review
  3. Review
  4. Immune myocarditis induced by sintilimab therapy: A case report.Experimental and therapeutic medicine · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mahlatse C M KgokoloDepartment of Dermatology, Faculty of Health Sciences, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Katherine AndersonDepartment of Dermatology, Faculty of Health Sciences, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Shalate C SiweleDepartment of Dermatology, Faculty of Health Sciences, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Helen C SteelDepartment of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Luyanda L I KwofieDepartment of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Mike M SathekgeDepartment of Nuclear Medicine, Faculty of Nuclear Medicine, Faculty of Health Sciences, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Pieter W A MeyerDepartment of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Bernardo L RapoportDepartment of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Ronald AndersonDepartment of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
University of Pretoria · ZANational Health Laboratory Service · ZASteve Biko Hospital · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xeroderma Pigmentosum (XP), an autosomal recessive disorder characterized by ultraviolet radiation-induced abnormalities of DNA excision and repair pathways is associated with early development of cutaneous cancers. Intracellular oxidative stress has also been proposed as a contributor to the occurrence of skin cancers. However, little is known about the possible augmentative contributions of chronic inflammation, immune suppression and oxidative stress to the pathogenesis of malignancies associated with other subtypes of XP. This has been addressed in the current study, focused on the measurement of systemic biomarkers of inflammation, immune dysfunction and oxidative damage in XP patients, consisting of XP-C, XP-D and XP-E cases, including those XP-C cases who had already developed multiple skin malignancies. The inflammatory biomarker profile measured in XP patients and healthy control subjects included the cytokines, interleukins (ILs)-2, -4, -6, -10, interferon-γ (IFN- γ) and tumor-necrosis factor-α (TNF-α), the acute phase reactant, C-reactive protein (CRP), and cotinine (as an objective indicator of smoking status). Immune suppression was detected according to the levels of five soluble inhibitory immune checkpoint proteins (CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3), as well as those of vitamin D, while oxidative stress was determined according to the circulating levels of the DNA adduct, 8-hydroxy-2-deoxyguanosine (8-OH-dG). These various biomarkers were measured in plasma using immunofluorimetric, nephelometric and ELISA procedures. Significant elevations in IL-6 (

Indexed as

8-hydroxy-2-deoxyguanosineC-reactive proteincutaneous malignanciescytokinesDNA excision/repairprogrammed death protein-1 (PD-1)soluble inhibitory immune checkpointsvitamin D

Identifiers

PMID35223501
PMCPMC8874270
OpenAlexW4211202238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.